As found in other tumors (Yang et al, 2019), preclinical models of melanoma intratumoral STING agonist (i.e., ADU S‐100) enhance tumor‐infiltrating T‐cells and reduced melanoma growth (Demaria et al, 2015; Chelvanambi et al, 2021), through a process depending on the expression of STING in noncancerous cells. Here, STING1 is linked to melanoma.